Evonik is investing in specialty lipids production for COVID-19 vaccines
23.04.2021
MOSCOW (MRC) -- Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines, said the company.Commercial lipid quantities are to be produced at Evonik's Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech. Evonik is making